An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Allergan

Status: Completed

Conditions: Macular Edema

Treatments: Drug: dexamethasone 700 ㎍ intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT02188173

GMA-US-EYE-0272

REINFORCE (Other Identifier)

Details and patient eligibility

About

This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of DME in at least one eye treated OZURDEX® per clinical practice

Exclusion criteria

• None

Trial design

200 participants in 1 patient group

dexamethasone 700 ㎍ intravitreal implant

Description:

Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.

Treatment:

Drug: dexamethasone 700 ㎍ intravitreal implant